Skip to main navigation

Investor Relations

  • Who We Are
    • Management
    • Board of Directors
  • Our Focus
    • Dismutase Mimetics
    • Reducing Oral Mucositis
    • Aiming to Increase Efficacy of Radiation Therapy
  • Our Pipeline
    • Avasopasem (GC4419)
    • Rucosopasem (GC4711)
    • Clinical Trials
    • Key Publications
  • Investors
    • IR Home
    • Press Releases
    • Events and Presentations
    • Stock Information
    • Corporate Governance
    • SEC Filings
    • Shareholder Services
  • Contact Us

Event Details

Galera ROMAN Phase 3 Trial Update

Dec 14, 2021 at 8:30 AM EST

Click here for webcast

Supporting Materials

View Presentation 1.8 MB

Investor Relations - Horizontal

IR Home
Press Releases
Events and Presentations
Stock Information
Corporate Governance
SEC Filings
Shareholder Services

Tools

Day High:
Day Low:
Volume:
Jul 18, 2022 12:35 AM EDT

Data Provided by Refinitiv.
Minimum 15 minutes delayed.

© Copyright 2022 Galera Therapeutics
Website Design & Development Graphic Beans
Privacy Policy – Terms of Use – Compassionate Use Policy

LinkedIn